Product information and disease descriptionProduct description
Phase of product development
11 evidence topics · 12 sources
Regulatory status: Submission planned; BLA planned for mid-2027
Launch
No evidence found.
BLA submission strategy for tumor HI and congenital HI to be set after upLIFT results
Phase 3 upLIFT study: preliminary primary endpoint result, November 2026
Phase 3 upLIFT study: enrollment completed, October 2026
FDA agreement to a single-arm, open-label upLIFT design, August 2025
FDA breakthrough therapy designation for tumor HI, May 2025
FDA orphan drug designation for tumor HI, November 2024
| Field | Quoted record |
|---|---|
| Generic name | “ersodetug” |
| Date designated | “11/20/2024” |
| Orphan designation | “treatment of hypoglycemia due to tumor-associated hyperinsulinism” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Rezolute Inc.” |
FDA clearance of the IND for the tumor HI phase 3 study, August 2024
European Union orphan designation for insulinoma, January 2024
| Field | Quoted record |
|---|---|
| Active substance | “Ersodetug” |
| Intended use | “Treatment of insulinoma” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/23/2879” |
| Date of designation | “12/01/2024” |
| Sponsor | “Rezolute (Bio) Ireland Limited” |
Designations granted for congenital HI only
| Field | Quoted record |
|---|---|
| Generic name | “fully human IgG2 monoclonal antibody that binds insulin receptors” |
| Date designated | “06/09/2015” |
| Orphan designation | “Treatment of congenital hyperinsulinism” |
| Sponsor | “Rezolute, Inc.” |